Ann Leen's most recent trade in Kalaris Therapeutics Inc. was a trade of 15,000 Common Stock done . Disclosure was reported to the exchange on Aug. 16, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Aug 2022 | 15,000 | 43,000 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 81,250 | 473,594 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 56,744 | 366,344 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 43,750 | 124,006 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 26,000 | 392,344 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 23,256 | 51,256 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jan 2022 | 14,000 | 65,256 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.26 per share. | 12 Nov 2021 | 14,266 | 2,294,876 | - | 22.3 | 317,628 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.92 per share. | 12 Nov 2021 | 6,122 | 2,288,254 | - | 21.9 | 134,167 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 23.18 per share. | 12 Nov 2021 | 500 | 2,294,376 | - | 23.2 | 11,588 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 21.76 per share. | 12 Nov 2021 | 100 | 2,288,154 | - | 21.8 | 2,176 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 22.75 per share. | 10 May 2021 | 150,000 | 2,309,142 | - | 22.8 | 3,412,500 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 16 Mar 2021 | 3,025 | 2,459,142 | - | 30.0 | 90,751 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.46 per share. | 01 Mar 2021 | 6,359 | 2,465,326 | - | 38.5 | 244,572 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.18 per share. | 01 Mar 2021 | 3,159 | 2,462,167 | - | 39.2 | 123,758 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.75 per share. | 19 Feb 2021 | 7,541 | 2,481,590 | - | 41.8 | 314,868 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 42.84 per share. | 19 Feb 2021 | 4,506 | 2,475,884 | - | 42.8 | 193,034 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.59 per share. | 19 Feb 2021 | 1,907 | 2,472,485 | - | 39.6 | 75,498 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.83 per share. | 19 Feb 2021 | 1,492 | 2,474,392 | - | 38.8 | 57,931 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.54 per share. | 19 Feb 2021 | 1,200 | 2,480,390 | - | 41.5 | 49,846 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 40.56 per share. | 19 Feb 2021 | 800 | 2,471,685 | - | 40.6 | 32,448 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.50 per share. | 18 Feb 2021 | 1,300 | 2,489,131 | - | 41.5 | 53,950 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 40.44 per share. | 18 Feb 2021 | 1,100 | 2,490,431 | - | 40.4 | 44,484 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.20 per share. | 18 Feb 2021 | 300 | 2,491,531 | - | 39.2 | 11,760 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.82 per share. | 16 Feb 2021 | 2,850 | 2,494,317 | - | 41.8 | 119,175 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.28 per share. | 16 Feb 2021 | 1,386 | 2,491,831 | - | 41.3 | 57,215 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.63 per share. | 16 Feb 2021 | 500 | 2,493,617 | - | 38.6 | 19,313 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.85 per share. | 16 Feb 2021 | 400 | 2,493,217 | - | 39.9 | 15,940 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 42.79 per share. | 16 Feb 2021 | 200 | 2,494,117 | - | 42.8 | 8,558 | Common Stock |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Jan 2021 | 60,394 | 0 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Jan 2021 | 60,394 | 60,394 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 28,000 | 28,000 | - | 0 | Common Stock | |
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | 03 Aug 2020 | 3,631,293 | 0 | - | - | Series A-3 Convertible Preferred Stock | ||
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | 03 Aug 2020 | 2,436,773 | 2,436,773 | - | - | Common Stock | ||
| Kalaris Therapeutics Inc. | Ann Leen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2020 | 257,600 | 257,600 | - | - | Stock Option (Right to Buy) |